Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: The experience of a single institution

Massimo Libra, Renato Talamini, Diana Crivellari, Angela Buonadonna, Andrea Freschi, Petar Stefanovski, Massimiliano Berretta, Marcello De Cicco, Luca Balestreri, Alberto Merlo, Rachele Volpe, Enzo Galligioni, Roberto Sorio

Research output: Contribution to journalArticlepeer-review

Abstract

Aim and background: Metastatic renal cell carcinoma is one of the few tumors for which a clear benefit of immunotherapy has been demonstrated. The aim of this study was to evaluate the long-term survival of patients with metastatic renal cell carcinoma, along with response rate and other prognostic and predictive factors. Patients and methods: Between July 1989 and May 1995, 56 patients with metastatic renal cell carcinoma were treated in a single institution with high-dose recombinant interleukin-2 in continuous infusion. Survival was measured by the Kaplan and Meier method. Prognostic factors were assessed by univariate and multivariate analyses of survival (Cox proportional hazard ratio model). Results: Of 56 patients, 15 had objective responses (26.8%), 16 stable disease (28.6%), 18 disease progressions (32.1%), and 7 (12.5%) were not valuable for response. Median overall survival was 20 months, and probability of 2- and 5-year survival was 41% and 21%, respectively. At multivariate analysis, the increased risk of death for: performance status ≥2 vs 0 (HR=6.20), stable disease (HR = 1.87), disease progression (HR = 10.61) vs partial or complete remission, and for hypotension and oliguria toxicity, G3 + G4 vs G1 + G2 (HR = 2.19). Conclusions: Our study confirms the activity of IL-2 based immunotherapy in renal cell carcinoma. Moreover, ECOG performance status, clinical response, hypotension and oliguria toxicity resulted as independent survival prognostic factors.

Original languageEnglish
Pages (from-to)400-404
Number of pages5
JournalTumori
Volume89
Issue number4
Publication statusPublished - Jul 2003

Keywords

  • Immunotherapy
  • Interleukin-2
  • Renal cell cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research

Fingerprint

Dive into the research topics of 'Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: The experience of a single institution'. Together they form a unique fingerprint.

Cite this